Tasquinimod + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castrate Resistant Prostate Cancer
Conditions
Metastatic Castrate Resistant Prostate Cancer
Trial Timeline
Jan 1, 2013 → May 1, 2015
NCT ID
NCT01732549About Tasquinimod + Placebo
Tasquinimod + Placebo is a phase 2 stage product being developed by Ipsen for Metastatic Castrate Resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01732549. Target conditions include Metastatic Castrate Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castrate Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02057666 | Phase 3 | Terminated |
| NCT01732549 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Castrate Resistant Prostate Cancer